Black Career Coach

Roche and Monte Rosa Therapeutics have entered into a collaboration and licensing agreement aimed at discovering and developing molecular glue degraders against targets in cancer and neurological diseases, with the deal potentially worth over $2bn. The partnership will utilise Monte Rosa’s QuEEN discovery engine and capabilities in identifying novel molecular glue degraders, which are designed to reprogramme the cell’s natural recycling machinery to selectively eliminate disease-causing proteins. The approach is believed to open up opportunities to eliminate therapeutically relevant proteins that are considered ‘undruggable’ by other small molecule approaches. Monte Rosa will lead discovery and preclinical activities against multiple select cancer and neurological disease targets "to a defined point,” it explained in a statement, while Roche will have the right to exclusively pursue further preclinical and clinical development of the resulting candidates. "Our QuEEN discovery engine, a highly validated and industry-leading molecular glue degrader platform, has been the cornerstone for Monte Rosa’s success, driving the discovery and development of our exquisitely selective molecular glue degraders successfully into the clinic,” said Markus Warmuth, chief executive officer of Monte Rosa. "This collaboration will enable and accelerate expansion of our platform into neuroscience and additional areas of oncology,” he added. Under the terms of the agreement, Monte Rosa will receive an upfront payment from Roche of $50m and will be eligible to receive future preclinical, clinical, commercial and sales milestone payments that could exceed $2bn, plus tiered royalties. The partners have also agreed on an option to expand the collaboration on multiple targets within the first two years, in which case additional payments for nomination, preclinical, clinical, commercial and sales milestones are due, as well as tiered royalties on the resulting products. James Sabry, global head of pharma partnering at Roche, said: "We believe that molecular glue degraders are a powerful new class of small molecules that target disease-related proteins that traditional approaches have been unable to address. "Together with Monte Rosa, we look forward to tackling high-value targets in both oncology and neuroscience with the goal of unlocking new therapeutic possibilities." Earlier this year, Roche entered into a new partnership with Alnylam Pharmaceuticals worth $2.8bn to develop and commercialise a potential treatment for high blood pressure. The candidate, zilebesiran, is an investigational, subcutaneously administered RNAi therapeutic in clinical development to treat hypertension in populations with high unmet needs. #ClinicalResearch #Pharmaceutical #Partnerships #ClinicalTrialPM #Roche #MonteRosa #Repost #Share from https://lnkd.in/eF4TdWXV

✨Exciting news✨Pfizer and Astellas' Xtandi has been granted FDA priority review for a new indication. This treatment is already approved in the US for three disease states of prostate cancer, making it a promising option for patients. Pfizer and Astellas announced that their androgen receptor signalling inhibitor, Xtandi (enzalutamide), has been granted priority review by the US Food and Drug Administration (FDA) to treat patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence (BCR). The treatment is already a standard of care in the US for metastatic castration-sensitive prostate cancer, metastatic castration-resistant prostate cancer and non-metastatic castration-resistant prostate cancer, and for one or more of these indications in more than 100 countries. Clinical Research Professionals please check out these innovative companies. #prostatecancer #FDA #healthcare #clinicaltrials #ClinicalResearch #ClinicalProjectManagement #Pfizer #Astellas https://lnkd.in/g_hKFZtj

Clinical Project Managers play a crucial role in the successful execution of clinical trials, which are critical for the development of new medical treatments and therapies. These professionals are responsible for planning, organizing, and overseeing all aspects of a clinical trial from start up to study closure. As the demand for clinical trials continues to grow, so does the need for skilled professionals who can effectively manage the many complexities involved in this crucial process. We created the Clinical Project Manager Certification Training Program for people who are new to the industry or looking to grow in Clinical research as a Project Manager. Participants will learn from experienced industry professionals and have the opportunity to apply their new skills through hands-on exercises and case studies. Our curriculum is tailored to meet the needs of professionals from a variety of backgrounds, including health professionals, project specialists, clinical research associates, coordinators, data, quality and regulatory specialists. Some of the key benefits of our program include: - Comprehensive review of Clinical Project Management, ICH & GCP - Timeline & Budget Development - Resource & Risk Management - PM Templates & SOPs - Expert instruction from experienced industry professionals - Hands-on exercises and case studies to reinforce learning - Flexible virtual options to accommodate busy professionals - Access to a supportive community of peers and mentors Contact us today to learn more. Take the survey below to see if this is a good fit for your goals or visit https://lnkd.in/e5WnhFfm to enroll. https://lnkd.in/gsFzsEDN #clinicaltrials #clinicalresearch #CRO #training #projectmanagement #clinicalprojectmanager #CCPM